ATE425744T1 - Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit - Google Patents

Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit

Info

Publication number
ATE425744T1
ATE425744T1 AT03761018T AT03761018T ATE425744T1 AT E425744 T1 ATE425744 T1 AT E425744T1 AT 03761018 T AT03761018 T AT 03761018T AT 03761018 T AT03761018 T AT 03761018T AT E425744 T1 ATE425744 T1 AT E425744T1
Authority
AT
Austria
Prior art keywords
pharmaceutical formulations
improved bioavailability
active ingredient
accordance
pharmaceutical formulation
Prior art date
Application number
AT03761018T
Other languages
English (en)
Inventor
Amir Shojaei
Henry Flanner
Scott Ibrahim
Beth Burnside
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE425744T1 publication Critical patent/ATE425744T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03761018T 2002-04-29 2003-04-29 Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit ATE425744T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37580302P 2002-04-29 2002-04-29

Publications (1)

Publication Number Publication Date
ATE425744T1 true ATE425744T1 (de) 2009-04-15

Family

ID=30000402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761018T ATE425744T1 (de) 2002-04-29 2003-04-29 Pharmazeutische formulierungen mit verbesserter bioverfugbarkeit

Country Status (9)

Country Link
US (1) US20040028729A1 (de)
EP (1) EP1499300B1 (de)
JP (1) JP2006511449A (de)
AT (1) ATE425744T1 (de)
AU (1) AU2003231777C1 (de)
CA (1) CA2483827C (de)
DE (1) DE60326709D1 (de)
ES (1) ES2322896T3 (de)
WO (1) WO2004000280A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382547A1 (en) * 1999-09-21 2001-03-29 Stephen R. Hanson Methods and compositions for treating platelet-related disosders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
DE202004021169U1 (de) * 2003-08-26 2007-03-01 Shire Holdings Ag Pharmazeutische Formulierung, die Lanthanverbindungen enthält
WO2005046655A1 (en) * 2003-11-04 2005-05-26 Shire Laboratories, Inc. Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
US8709476B2 (en) 2003-11-04 2014-04-29 Supernus Pharmaceuticals, Inc. Compositions of quaternary ammonium compounds containing bioavailability enhancers
DE602004030931D1 (de) * 2003-11-04 2011-02-17 Supernus Pharmaceuticals Inc
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
NZ556630A (en) * 2005-01-27 2010-12-24 Alembic Ltd Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer
JP2009511606A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
EA200801080A1 (ru) * 2005-10-14 2009-02-27 Х. Лундбекк А/С Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
AU2007319141B2 (en) 2006-11-17 2013-01-10 Supernus Pharmaceuticals Inc. Sustained-release formulations of topiramate
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US8202542B1 (en) * 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US20120321674A1 (en) * 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
MX2012011051A (es) * 2010-03-25 2013-01-29 Aop Orphan Pharmaceuticals Ag Composicion novedosa para el tratamiento de trombocitemia esencial.
CA2827273A1 (en) * 2011-02-17 2012-08-23 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
US20150086627A1 (en) * 2012-03-29 2015-03-26 Halo Therapeutics, Llc. Dosage forms of halofuginone and methods of use
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
IT201800011125A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
IT202000011053A1 (it) 2020-05-14 2021-11-14 Int Health Science S R L Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di alimenti, integratori alimentari, nutraceutici, dispositivi medici
IT202000011050A1 (it) 2020-05-14 2021-11-14 Mogon Pharmaceuticals Sagl Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5520932A (en) * 1988-06-24 1996-05-28 The Upjohn Company Fine-milled colestipol hydrochloride
US5372823A (en) * 1989-03-16 1994-12-13 Bristol-Myers Squibb Company Direct compression cholestyramine tablet and solvent-free coating thereof
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5405648A (en) * 1993-05-10 1995-04-11 Hermann; Paul F. Coating particulate material with a polymer film
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DE19724696A1 (de) * 1997-06-12 1998-12-24 Hexal Ag Pharmazeutische Zubereitung mit drei Pelletarten
NZ513037A (en) * 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
US6576619B2 (en) * 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
DE60230546D1 (de) * 2001-10-26 2009-02-05 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe

Also Published As

Publication number Publication date
ES2322896T3 (es) 2009-07-01
EP1499300B1 (de) 2009-03-18
WO2004000280A1 (en) 2003-12-31
CA2483827C (en) 2012-01-24
CA2483827A1 (en) 2003-12-31
DE60326709D1 (de) 2009-04-30
JP2006511449A (ja) 2006-04-06
EP1499300A4 (de) 2006-04-12
AU2003231777A1 (en) 2004-01-06
US20040028729A1 (en) 2004-02-12
AU2003231777B2 (en) 2008-12-18
EP1499300A1 (de) 2005-01-26
AU2003231777C1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
DE60326709D1 (de) Pharmazeutische formulierungen mit verbesserter bioverfügbarkeit
CY1120138T1 (el) Στερεη φαρμακευτικη μορφη δοσολογιας που περιλαμβανει μια στερεη διασπορα αναστολεα πρωτεασης toy hiv
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
DK1545467T3 (da) Faste farmaceutiske formuleringer omfattende telmisartan
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
EP1589947B8 (de) Pharmazeutische formulierung enthaltend einen unlöslichen wirkstoff zur pulmonalen verabreichung
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
FIU20070036U0 (fi) Amorfisen aktiivisen ainesosan stabiloitu farmaseuttinen valmiste
FI4823U1 (fi) Muunnetulla tavalla vapauttava lääkeformulaatio
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
MX2007002898A (es) Tableta con liberacion gastrointestinal controlada en sitio y tiempo del ingrediente activo.
BG108516A (en) Pharmaceutical formulation
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
IS7065A (is) Áætlun um lyfjaskammta við meðferð og lyfjasamsetningar til getnaðarvarna í neyð
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
DE60320039D1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
MY141008A (en) Oral formulations of deoxypeganine and their uses
TR200701266T1 (tr) Farmasötik bileşim.
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties